ReviewCancer cell international2025
Post-translational modifications in anaplastic thyroid carcinoma: biological mechanisms and therapeutic potential.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Anaplastic thyroid carcinoma (ATC) remains one of the most lethal tumors, exhibiting a high recurrence rate, mortality rate and resistance to treatment. Post-translational modifications (PTMs) influence protein function by altering protein structure and play a crucial role in key signal transduction events related to tumor transformation and carcinogenesis, mainly including phosphorylation, ubiquitination, acetylation, and glycosylation. We highlight that dysregulation of PTM-mediated cascades in core proteins or signaling pathways serves as key factors in ATC progression. Phosphorylation, acetylation, and ubiquitination, along with the activation of various pathways, are associated with the proliferation, invasion, and metastasis of ATC. The first two PTMs significantly contribute to both targeted drug synthesis and the development of treatment resistance. Additionally, glycosylation is linked to the de-differentiation of ATC and offers an approach for new therapeutic strategies. Moreover, we discuss the potential of PTMs as biomarkers and therapeutic targets for ATC. Different PTMs play a crucial role in the application of various therapeutic approaches, particularly in the context of targeted drugs. These modifications underlie the molecular mechanisms for the selection of corresponding drugs and contribute to resistance. This review aims to provide a comprehensive understanding of the biological processes by which multiple PTMs co-regulate ATC by exploring the interplay of PTMs and their impact on ATC progression. Besides, there are still some gaps and unresolved issues in this field. By integrating different insights, we emphasize the progress in tools for early intervention to improve the prognosis of patients with ATC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.